The atlas of RNase H antisense oligonucleotide distribution and activity in the CNS of rodents and non-human primates following central administration. Issue 2 (24th December 2020)

• Record Type: Journal Article
• Authors: Jafar-nejad, Paymaan; Powers, Berit; Soriano, Armand; Zhao, Hien; Norris, Daniel A; Matson, John; DeBrosse-Serra, Beatrice; Watson, Jamie; Narayanan, Padmakumar; Chun, Seung J; Mazur, Curt; Kordasiewicz, Holly; Swayze, Eric E; Rigo, Frank
• Is Part Of: Nucleic acids research. Volume 49:Issue 2(2021)
• Page Start: 657
• Page End: 673
• Publication Date: 2020-12-24
• Subjects: Nucleic acids -- Periodicals; Molecular biology -- Periodicals; 572.805
• DOI: 10.1093/nar/gkaa1235
• Languages: English
• ISSNs: 0305-1048

Abstract

Abstract: Antisense oligonucleotides (ASOs) have emerged as a new class of drugs to treat a wide range of diseases, including neurological indications. Spinraza, an ASO that modulates splicing of SMN2 RNA, has shown profound disease modifying effects in Spinal Muscular Atrophy (SMA) patients, energizing efforts to develop ASOs for other neurological diseases. While SMA specifically affects spinal motor neurons, other neurological diseases affect different central nervous system (CNS) regions, neuronal and non-neuronal cells. Therefore, it is important to characterize ASO distribution and activity in all major CNS structures and cell types to have a better understanding of which neurological diseases are amenable to ASO therapy. Here we present for the first time the atlas of ASO distribution and activity in the CNS of mice, rats, and non-human primates (NHP), species commonly used in preclinical therapeutic development. Following central administration of an ASO to rodents, we observe widespread distribution and target RNA reduction throughout the CNS in neurons, oligodendrocytes, astrocytes and microglia. This is also the case in NHP, despite a larger CNS volume and more complex neuroarchitecture. Our results demonstrate that ASO drugs are well suited for treating a wide range of neurological diseases for which no effective treatments are available.